Penn Davis McFarland’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,565
| Closed | -$262K | – | 48 |
|
|
2023
Q2 | $262K | Hold |
2,565
| – | – | 0.05% | 42 |
|
|
2023
Q1 | $233K | Buy |
+2,565
| New | +$233K | 0.04% | 43 |
|
|
2021
Q4 | – | Sell |
-2,565
| Closed | -$258K | – | 46 |
|
|
2021
Q3 | $258K | Hold |
2,565
| – | – | 0.05% | 43 |
|
|
2021
Q2 | $363K | Hold |
2,565
| – | – | 0.06% | 39 |
|
|
2021
Q1 | $256K | Sell |
2,565
-1,283
| -33% | -$128K | 0.05% | 42 |
|
|
2020
Q4 | $476K | Hold |
3,848
| – | – | 0.1% | 34 |
|
|
2020
Q3 | $375K | Hold |
3,848
| – | – | 0.1% | 35 |
|
|
2020
Q2 | $600K | Hold |
3,848
| – | – | 0.16% | 32 |
|
|
2020
Q1 | $555K | Sell |
3,848
-1,283
| -25% | -$185K | 0.19% | 28 |
|
|
2019
Q4 | $1.05M | Buy |
+5,131
| New | +$1.05M | 0.31% | 23 |
|